Navigation Links
Lung Cancer Alliance Hails Massachusetts State Senator for Taking Lead on Lung Cancer
Date:1/15/2009

For Second Straight Year, Legislation Introduced to Fund Lung Cancer Research

BOSTON, Jan. 15 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) hailed Senator Susan Fargo (D-3rd Middlesex), the Senate Chair of the Joint Committee on Public Health, for once again introducing comprehensive legislation that creates a trust fund for lung cancer research.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO)

"Now is the time for positive change for lung cancer in Massachusetts," said Joanne O'Connor, LCA-Massachusetts (LCA-MA) Co-chair. "On behalf of those touched by lung cancer in Massachusetts, we thank Senator Fargo for her continued leadership in addressing the critical need for increased lung cancer research."

Lung cancer is the leading cause of cancer deaths nationally and in Massachusetts. Lung cancer claims more lives each year than breast, prostate, and colon cancers--combined. In 2008, an estimated 4,930 Massachusetts citizens were diagnosed with lung cancer and 3,600 were lost to the disease. Over 70% are diagnosed at a late stage accounting for the low 15% survival rate.

"There are too few opportunities for the research community to tackle lung cancer and make an impact on survival rates," said Senator Fargo. "This legislation is intended to drive lung cancer research forward in many different areas as well as to allow researchers to find innovative new methods of diagnosing and treating the disease."

"This bill provides the funding needed to institute innovative lung cancer screening programs for those at high risk throughout the state, especially rural and underserved populations," said Diane Legg, lung cancer survivor and LCA-MA Co-chair. "In addition, the bill enhances research that has been lacking on targeted therapies, chemoprevention, and disparities."

The bill, introduced this week, establishes screening programs for the high risk population, promotes the development of new diagnostic and screening technologies for lung cancer, supports research into the disparities surrounding lung cancer incidence and mortality rates, and supports research to discover cures through the development of chemoprevention and targeted therapies.

"I commend Senator Fargo for her work in raising awareness of lung cancer as an under-recognized and under-funded health priority," Yolonda Colson, MD, PhD, Associate Professor of Surgery, Division of Thoracic Surgery and Director, Women's Lung Cancer Program at Brigham and Women's Hospital.

"We are committed to working with Senator Fargo, other members of the state legislature, public health organizations and all who share our goal of reducing lung cancer's mortality rates through increased research funding," O'Connor said.

Lung Cancer Alliance (www.LungCancerAlliance.org) is the only national non-profit organization dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer. Lung Cancer Alliance is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

    Media Contact:
    Joanne O'Connor
    joconnor@lungcanceralliance.org
    781-335-4727


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... "ProBrand Flip ... and all media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand ... easy to use drop zones. Editors can select from a variety of flip book ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... to present at the International Probiotic Association’s Washington DC workshop on November 2nd. ... to engage in dialog regarding probiotic dietary supplement regulations. , Dr. Leyer ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... because of a higher risk of serious health problems, such as cardiovascular illness, ... Dr. Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... WESTLAKE VILLAGE, Calif. , Dec. 6, ... a privately held, clinical-stage medical dermatology and ... Creabilis plc, a privately held specialty pharmaceutical ... for common inflammatory skin conditions, including psoriasis, ... terms of the agreement, Sienna will make ...
(Date:12/6/2016)... Calif. , Dec. 6, 2016  Regulus ... biopharmaceutical company leading the discovery and development of ... drug development candidates at its R&D day, held ... first candidate, RGLS5040, is an anti-miR targeting microRNA-27 ... second candidate, RGLS4326, is an anti-miR targeting microRNA-17 ...
(Date:12/6/2016)... - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: ... in the use of cannabinoids for the treatment ... 2015 InMed initiated its COPD program using its ... potential active compounds that can be useful for ... assays using human lung fibroblasts (HFL-1 cell line), ...
Breaking Medicine Technology: